Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096297 · ClinicalTrials.gov registry record · Phase 2
Luspatercept + Darbepoetin in MDS
A Phase 2 study of MDS (Myelodysplastic Syndrome), sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT07096297 is a Phase 2 study of MDS (Myelodysplastic Syndrome) that is actively recruiting participants, run by Yale University. The registered enrollment target is 60 participants, below the 113-participant average among 6 other MDS (Myelodysplastic Syndrome) trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07096297, a Phase 2 study of MDS (Myelodysplastic Syndrome), is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
Conditions Studied
Interventions
- DRUG Luspatercept
- DRUG Darbeopoetin
Study Locations (3)
Connecticut
- Yale University - New Haven
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Texas
- Harold C. Simmons Comprehensive Cancer Center of UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07096297
The ClinicalTrials.gov registry entry for NCT07096297 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 6 other MDS (Myelodysplastic Syndrome) trials with a reported enrollment target (47% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MDS (Myelodysplastic Syndrome) appearing as the primary indexed condition, and to 2 interventions - of which Luspatercept is the first listed.
NCT07096297 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT07096297 about?
NCT07096297 is a clinical study titled "Luspatercept + Darbepoetin in MDS". This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
What is the current status of trial NCT07096297?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-16. Estimated completion is 2030-08.
What conditions does trial NCT07096297 study?
This clinical trial studies the following conditions: MDS (Myelodysplastic Syndrome).
What interventions are being tested in trial NCT07096297?
The interventions under investigation include: Luspatercept (DRUG), Darbeopoetin (DRUG).
Who is sponsoring clinical trial NCT07096297?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096297 being conducted?
This trial has 3 study locations across Connecticut, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS (Myelodysplastic Syndrome)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
RECRUITING · Phase 1
-
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
RECRUITING · Phase 1
-
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.